News

August 8, 2016 9:30 am
Update on NLB and their publications
August 1, 2016 4:45 pm
New Categories of Minimal Residual Disease (MRD) Negativity Provide Clinical Trial Endpoints and Framework for Cure
August 1, 2016 4:45 pm
FDA action underscores potential clinical benefit of daratumumab as a backbone therapy in combination with either a proteasome inhibitor (PI) or an immunomodulatory agent for patients who have received at least one prior therapy. Marks the second...
August 1, 2016 4:45 pm
Dr. Shaji Kumar of the Mayo Clinic in Rochester, Minnesota, discusses the exciting new Black Swan Research Initiative® clinical trial: ASCENT, which stands for Aggressive Smoldering Cure Evaluating Novel Rx Transplant. In the ASCENT trial (which...

Pages